THJ-2201 is an indazole-based synthetic cannabinoid that presumably acts as a potent agonist of the CB1 receptor and has been sold online as a designer drug. It is a structural analog of AM-2201 in which the central indole ring has been replaced by indazole.
Pharmacology THJ-2201 acts as a full agonist with a binding affinity of 1.34 nM at CB1 and 1.32 nM at CB2 cannabinoid receptors.
Side effects THJ-2201 has been linked to at least one hospitalization and death due to its use.
Legal status It is classified as a Schedule I controlled substance in the United States. It is also an Anlage II controlled drug in Germany.
See also AM-694 AM-1235 AM-2232 AM-2233 FUBIMINA JWH-018 List of AM cannabinoids List of JWH cannabinoids NM-2201 THJ-018
References


